Activation of the Wnt/-catenin signaling is reported in large subsets of hepatocellular carcinoma (HCC). Upregulation of Wnt genes is one contributing mechanism. In the current study, we sought to address the role of hepatocyte-derived Wnts in a model of hepatic injury, fibrosis and carcinogenesis. We subjected hepatocyte-specific Wntless knockout mice (HP-KO), unable to secrete Wnts from hepatocytes, and littermate controls (HP-CON), to diethylnitrosamine and carbon tetrachloride (DEN/CCl 4 ) and harvested at 3, 5, and 6 months for histological and molecular analysis. Analysis at 5 months displayed increased hepatic expression of several Wnts and upregulation of some but not all -catenin targets, without mutations in Ctnnb1. At 5 months, HP-CON and HP-KO had comparable tumor burden and injury, however HP-KO uniquely showed small CK19-positive foci within tumors. At 6 months both groups were moribund with comparable tumor burden and CK19-positivity. While HCC histology was indistinguishable between the groups, HP-KO exhibited increased active-β-catenin, and decreased c-Myc, Brd4, E-Cadherin, and others. Hepatic injury, inflammation and fibrosis were also indistinguishable at 3 months between both groups. Thus, lack of Wnt secretion from hepatocytes did not affect overall injury, fibrosis or HCC burden although there were protein expression differences in the tumors occurring in the two groups.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the 6 th commonest malignancy worldwide, with a median survival of 11 months and increasing incidence rates 1 . While liver transplant is a promising treatment for a subset of patients, factors including lack of donor organs and failure to meet Milan criteria make transplant an unlikely option. FDAapproved therapies Sorafenib and Regorafenib, while helpful and limit HCC progression, extend patient survival by 3 months 2, 3 . Further, HCC develops in cirrhotic livers in 70-90% of cases, resulting from chronic liver injuries of all etilogies 4 . Due to increasing rates of liver diseases leading to fibrosis and tumorigenesis, the need for improved therapies to target and prevent HCC is growing.
β-Catenin signaling is upregulated in 20-90% of HCC patients 5 . -Catenin is part of the Wnt signaling pathway with many roles in liver pathophysiology 6 . -Catenin activation in HCC can result from mutations in Ctnnb1, the gene encoding for -catenin, or other mechanisms including overexpression of Wnt and its receptor Frizzled (Fzd) 7 .
In fact, overexpression of many Wnts and Fzds have been implicated in different cancers including HCC [7] [8] [9] and several HCC cell lines 10 . These modifications result in increased nuclear accumulation of β-catenin, leading to transcriptional upregulation of target genes and promotion of tumorigenesis 9 . When Wnt antagonist fusion proteins are injected into an orthotopic HCC model harboring wildtype β-catenin, animal survival increases, and tumor volume, β-catenin activity, and angiogenesis decreases, suggesting that Wnts may be a promising therapeutic target 11 . There are Wnt inhibitors in phase I clinical trials for solid tumors which may be effective for HCC patients with wildtype β-catenin (NCT01351103), (NCT01608867). Furthermore, patients with activated wild-type β-catenin resulting from Wnt or Fzd activation have more aggressive, dedifferentiated tumors and poorer prognosis than those with mutated β-catenin, yet less is known about the mechanism of wild type β-catenin in tumor progression 8 .
The main goal of our study was to assess hepatocytes as a source of Wnts which may be essential in chronic liver injury, fibrosis and HCC. We first confirmed a model of chronic injury (diethylnitrosamine and carbon tetrachloride, or DEN/CCl 4 )
induced HCC and simultaneously induced transcriptional upregulation of Wnts, -catenin activation, but not Ctnnb1 mutations, consistent with previous reports 12 . We next assessed whether Wnts from hepatocytes may be required for tumorigenesis after DEN/CCl 4 . We utilized hepatocyte-specific Wntless knockout mice unable to secrete
Wnts from hepatocytes (HP-KO) 13 . We subjected HP-KO and littermate controls (HP-CON) to DEN/CCl 4 until 5 months of age. Comparable tumors were observed in HP-KO and HP-CON, although we observed small CK19-positive foci in HP-KO. Overall, HCC behaved analogously in HP-KO and HP-CON up to 6 months despite increased activated β-catenin expression and decreased c-Myc, Brd4, Erk1/2, Bax, and Ecadherin expression in HP-KO. We also assessed HP-CON and HP-KO at an early time-point, but did not detect any differences in the injury microenvironment. Thus, our data suggests that hepatocyte-specific Wnts do not contribute to injury and fibrosis, but do participate in HCC development and their loss leads to comparable tumor burden and histology in response to DEN/CCl 4 .
MATERIALS AND METHODS

Animals.
Animal work was performed in accordance with the Institutional Animal Care
and Use Committee at the University of Pittsburgh. Albumin-Cre Wntless knockout mice were generated as described previously 13 . Male pups (HP-KO, HP-CON) were injected with 25mg/kg diethylnitrosamine (Sigma) at 14-16 days prepared in sterile 0.9% saline.
Animals were transferred to a BSL2+ facility and injected with 0.5ml/kg carbon tetrachloride (CCl 4 ) twice per week from week 8 to 22, prepared in corn oil. Three days after the last injection, animals were sacrificed (n=4) and livers were harvested. Livers were also harvested from a pre-cancer time-point of 3 months (n=3) and advancedcancer time-point of 6 months (n=4). Animals were monitored daily for signs of morbidity. At time of sacrifice, liver weights (LW) and body weights (BW) were assessed for LW/BW and differences tested for significance by Student's T Test with p<0.05 to be considered significant. Blood was collected from the inferior vena cava and serum was sent to the University of Pittsburgh Medical Center Clinical Laboratory for ALT, AST, and ALP testing.
Immunohistochemistry. Paraffin sections were processed as described elsewhere 14 .
Sirius Red, Ki67, H&E, CD45, CK19 and GS staining was performed as also described in detail previously 14 .
Protein isolation and analyses. Protein was extracted in RIPA buffer, quantified, and 30µg was loaded onto a precast BioRad SDS gel. Gels were transferred using BioRad semi-dry transfer system. Antibody information can be found in 16, 17 . This model utilizes one injection of diethylnitrosamine at day 15, and biweekly injections of carbon tetrachloride from week This model is known to cause HCC without β-catenin mutations as confirmed through sequencing and supported by lack of GS staining 12 , which is a surrogate, albeit debated, for mutated β-catenin 18, 19 . Via immunohistochemistry, all tumors were GSnegative ( Figure 1C ). Further, tumors were sequenced for mutations in exon 2 of Ctnnb1, analogous to exon 3 in humans. This is home to GSK3β phosphorylation sites and the most frequent activating mutations in HCC 15, 20 . Wildtype Ctnnb1 was identified in all tumors ( Figure 1D ). This was also corroborated using microarray data obtained from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/), accession number GSE33446, comparing data from DEN/CCl 4 treated animals to untreated animals 16 . We queried the data and noted no change in expression of Glul, gene encoding for GS, after DEN/CCl 4 . However, several -catenin targets were upregulated as listed in Table   3 suggesting that modest activation of the pathway does occur despite absent Ctnnb1 mutations.
Next, we assessed whether Wnts were overexpressed after DEN/CCl 4 , and tested mRNA expression of select Wnts in livers after DEN/CCl 4 compared to untreated livers. Wnt1, Wnt6, Wnt10a, Wnt10b, Wnt11, and Wnt16 showed upregulation of at least two-fold in DEN/CCl 4 livers versus control livers ( Figure 1E ). We hypothesized that atleast some of these may be originating from hepatocytes and hence interrogated tumorigenesis in mice lacking ability to secrete all Wnts from hepatocytes owing to Wntless loss. No difference in tumor burden in HP-KO versus HP-CON at advanced stages. We predicted CK19-positive foci in HP-KO to develop into more aggressive tumors than HP-CON. To test this, we followed an independent cohort for an additional timeframe.
HP-KO and HP-CON
However, by 6 months, all mice became moribund and required euthanasia. Grossly, livers from both groups were excessively stiff and showed sizable tumor burden ( Figure   3B ). LW/BW at 6 months failed to show significant differences between the two groups and both groups showed increased ratios over the 5-month time-point ( Figure 3C ).
Mutations in Ctnnb1 were still absent at 6 months ( Figure 3D) . Intriguingly, at 6 months, both HP-CON and HP-KO displayed comparable, diffuse, and broader staining for CK19
within tumors ( Figure 3E ). Similar to 5-month time-point, comparable fibrosis, inflammation and proliferation was observed as seen by Sirius red ( Figure 3E ), CD45, and Ki67 staining, respectively (data not shown). Thus, there were no phenotypic differences in HCC occurring in HP-CON and HP-KO at 6 months after DEN/CCl 4 .
HP-CON and HP-KO after DEN/CCl 4 show distinct temporal protein expression.
Despite comparable tumor burden and histology in HP-CON and HP-KO at 5 and 6 months, we queried whether there are differences in protein expression, likely correlating with altered signaling patterns, as a result of absent Wnt secretion from hepatocytes. First, we assessed proliferation markers and relevant β-catenin activation markers via western blot ( Figure 4A, 4C) . Hypo-phosphorylated β-catenin, suggesting activation, was comparable at 5 months and significantly upregulated in HP-KO at 6 months. GS was variable, while Cyp2e1, a -catenin target altered by CCl 4 , was lower in HP-KO at 5 months, although levels in both HP-CON and HP-KO were comparably reduced at 6 months. Total levels of β-catenin were comparably reduced at 6 months compared to 5 months. Cyclin-D1 was increased at 6 months compared to 5 months in both groups. PCNA remained comparably high at all times in both groups. Intriguingly, c-Myc was reduced in HP-KO at both 5 and 6 months. Thus, overall hepatocyte-specific loss of Wnts appears to promote β-catenin hypo-phosphorylation and decrease c-Myc levels after DEN/CCl 4 .
We sought a holistic approach to assess protein levels, and performed Reverse
Phase Protein Array to assess expression of over 240 proteins involved in cancer as described in Methods. Several proteins had significant differences between HP-CON and HP-KO in the 5 month or 6 month time-point, and select proteins were confirmed by western blot (Figure 4B, 4D) . Intriguingly, at 5 months HP-KO had significantly less expression of ERK1/2, Bax, Brd4, and E-cadherin than HP-CON. By 6 months, HP-KO had increased ERK1/2 and decreased Brd4, and comparable Bax and E-cadherin.
Expression of Wee1, Yap, and Cdc25 were variable, and while PKAa expression was only evident at 6 months, there was no difference between HP-CON and HP-KO ( Figure   4B , 4D). Taken together, this suggests HP-specific Wnts temporally regulate expression of oncogenes including ERK1/2, Bax, E-cadherin, and Brd4. 
DISCUSSION
Activation of Wnt/-catenin signaling in HCC is due to various mechanisms 5, 22 . .
Upon challenging HP-CON and HP-KO with DEN/CCl 4 , comparable tumor burden was observed at 5 months. We noted similar injury, fibrosis, inflammation, and proliferation. However, in assessing tumor differentiation, we observed the presence of small but frequent CK19-positive foci within larger CK19-negative tumors, in HP-KO.
Presence of CK19 in HCC is suggested to correlate with a more dedifferentiated phenotype, overall poor prognosis and worse outcome after surgery [26] [27] [28] . Finding CK19-positive foci in HP-KO was surprising, since a positive correlation between Wnt/β-catenin activation and stem markers including CK19 has been previously reported 29 .
However, since secretion of all Wnts is being disrupted, it is likely that the loss of noncanonical Wnts may be allowing for increased CK19 positivity. Indeed, hepatocytes and transformed hepatocytes are known to be a source of non-canonical Wnts that suppress β-catenin activity 10 . Intriguingly, the increased numbers of CK19-positive foci did not lead to an overall aggressive HCC in HP-KO at 6 months and both groups of mice succumbed to excessive tumor burden, and CK19 staining was comparable at this timepoint. These data suggest that the DEN/CCl 4 model is too robust leading to an aggressive disease and a model with an indolent course may be more suitable to address the overall role of hepatocyte-derived Wnts.
We also noted a reduction in c-Myc in HP-KO at 5 months and 6 months. Wnt/β-Catenin activates c-Myc, particularly during hepatocarcinogenesis . At 5 month and 6 month timepoints, cMyc and Brd4
were both reduced in HP-KO. Whether HP-Wnts regulate cMyc through Brd4 remains a plausible mechanism to assess. E-cadherin inversely correlates with aggressive HCC, as loss leads to increased epithelial to mesenchymal transition and invasiveness 34 .
Reduction of E-cadherin in HP-KO at 5 months, then comparable expression to HP-CON at 6 months, supports the findings that at 5 months HP-KO tumors began to dedifferentiate, but all differences are ablated by 6 months. This likely reaffirms the model is too hepatotoxic to appreciate contributions of HP Wnts, as other pathways are able to compensate. E-cadherin can activate ERK signaling in other cancers 35 , which may explain why reduced E-cadherin correlates with reduced ERK1/2 at 5 months, however further studies are required to confirm pathway activation. Finally, the role of HP-Wnts in Bax expression is unclear, despite HP-KO having reduced Bax at 5 months.
Overall, we conclude HP-Wnts contribute to protein expression, which likely corresponds to signaling changes but are insignificant to the overall tumor phenotype.
Wnt signaling from hepatocytes also appears to not influence the overall pretumor environment. At 3 months, comparable injury, inflammation, and fibrosis was observed between HP-CON and HP KO. This negative data is novel and important, as we provide in vivo evidence that targeting hepatocyte-specific Wnts will not be an effective clinical therapy, despite literature demonstrating increased Wnts in HCC and transformed hepatocytes in vitro. It will be of interest to assess Wnt contributions from additional cell types, including macrophages and endothelial cells, to identify roles to injury, fibrosis, and carcinogenesis. 
